profit from every $100 of sales.
$0$100
DBV Technologies
$11.02-3.63% today
-15.7% in 1 year
1-year low $8.871-year high $24.54
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What DBV Technologies sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$147 million of profit last year.
SalesProfit
DBV Technologies vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| DBV Technologies | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads DBV Technologies's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -97 | -76 | -117 | -147 | |
| -83 | -67 | -109 | -139 | |
| -96 | -73 | -114 | -147 | |
| -6.20 | -3.80 | -5.85 | -5.25 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 247 | 183 | 66 | 234 |
| Cash | 209 | 141 | 32 | 194 |
| Total debt | 4 | 7 | 8 | 8 |
| Total liabilities | 52 | 43 | 38 | 65 |
| 194 | 140 | 27 | 169 | |
| 16 | 19 | 19 | 28 | |
| -38.4% | -41.1% | -261.8% | -65.7% | |
| -49.5% | -51.9% | -415.9% | -87.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -56 | -80 | -104 | -121 | |
| 1 | 1 | 2 | 1 | |
| -56 | -80 | -107 | -122 | |
| Dividends paid | – | – | – | – |
| – | 0 | 0 | – | |
| 5 | 6 | 5 | 5 |
Valuation
- –
- –
- –
- 7.7×
- –
- –
- –
- -17.5%
- -21.2%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -74.6%
- -117.5%
- -130.1%
- -63.0%
- -80.2%
- –
Growth
- –
- –
- −13.4%
- –
- +11.9%
Financial health
- 1.4×
- 0.03
- 2.3%
- -265.5×
- 4.76
- 4.76
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 2%of 964
Bottom 19%of 898
Bottom 4%of 991
What analysts expect
- Average price target
- $46.33
- Range
- $40.00 – $51.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | -0.56 | -0.14 | −300.0% |
| Mar 27, 2026 | -1.15 | -1.30 | +11.5% |
| Oct 28, 2025 | -1.20 | -1.45 | +17.2% |
| Jul 29, 2025 | -1.55 | -0.21 | −638.1% |
| Apr 30, 2025 | -0.26 | -0.24 | −8.3% |
| Mar 27, 2025 | -1.20 | -2.00 | +40.0% |
| Nov 6, 2024 | -0.80 | -1.90 | +57.9% |
| Jul 30, 2024 | -1.70 | -1.30 | −30.8% |
News
Dell Technologies (DELL) Will Build An Alabama Research Computing CenterYahoo Finance · Nov 14, 2026Ocean Power Technologies plunges 42% after pricing $3M offeringSeeking Alpha · Nov 13, 2026ABAXX Technologies reports Q3 resultsSeeking Alpha · Nov 12, 2026Lumen Technologies (LUMN) Could Be 47% Undervalued On Fresh Third Quarter ResultsYahoo Finance · Nov 8, 2026bioAffinity Technologies GAAP EPS of -$5.89, revenue of $1.1MSeeking Alpha · Nov 6, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
30No pass
Benjamin Graham
40No pass
Philip Fisher
31No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
24No pass
Terry Smith
22No pass
Questions about DBV Technologies
Is DBV Technologies a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the DBV Technologies AI analysis
What does DBV Technologies do?
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. It is in Biotechnology.
Does DBV Technologies pay a dividend?
No. DBV Technologies does not pay a dividend at the moment.
Is DBV Technologies stock halal?
Yes. DBV Technologies passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has DBV Technologies stock done over the past year?
Down 15.7% over the past twelve months, to $11.02. It traded between $8.87 and $24.54 and is 55.1% below its high.
Who are DBV Technologies's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with DBV Technologies's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.